ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung clinical trials

A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined with Chemotherapy in Children, Adolescents and Young Adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

This study looks at a new drug, Gilteritinib, combined with standard chemotherapy for children, teenagers, and young adults with a specific type of leukaemia (AML) that has come back or not responded to previous treatment. Researchers want to find the best dose and see how well it works.